We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Aponermin: First Approval.
- Authors
Dhillon, Sohita
- Abstract
Aponermin (沙艾特) is a recombinant circularly permuted human tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) developed by Beijing Sunbio Biotech (a wholly owned subsidiary of Wuhan Hiteck Biological Pharma CO., LTD) for the treatment of multiple myeloma. Aponermin binds to and activates the death receptors 4 and/or 5 on tumour cells, triggering intracellular caspase reactions and inducing apoptosis, thereby exerting antitumor effects. In November 2023, aponermin in combination with thalidomide and dexamethasone received its first approval in China for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two prior therapies. This article summarizes the milestones in the development of aponermin leading to this first approval for relapsed or refractory multiple myeloma.
- Subjects
CHINA; MULTIPLE myeloma; COMBINATION drug therapy; LIGANDS (Chemistry); PLACEBOS; APOPTOSIS; THALIDOMIDE; CELLULAR signal transduction; DRUG approval; PHARMACY information services; TUMOR necrosis factors; DEXAMETHASONE
- Publication
Drugs, 2024, Vol 84, Issue 4, p459
- ISSN
0012-6667
- Publication type
Article
- DOI
10.1007/s40265-024-02004-9